中枢神经系统非生殖细胞胚胎细胞瘤的最佳治疗策略:系统性审查和元分析
Zhirui Zhou1, Xiwei Zhang2, Lin Zheng3
1Radiation Oncology Center, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai 200040, China; National Center for Neurological Disorders, Shanghai 200052, China.
Critical reviews in oncology/hematology
|January 15, 2025
概括
中枢神经系统非胚芽细胞瘤 (NGGCTs) 的最佳治疗包括粗整切除 (GTR) 和脊辐射 (CSI). 组合化疗进一步降低了失败风险,可能允许减少放射治疗剂量.
科学领域:
- 神经瘤学神经瘤学
- 儿科瘤学 儿科瘤学
- 辐射瘤学 辐射瘤学
背景情况:
- 中枢神经系统 (CNS) 的非胚芽细胞瘤 (NGGCTs) 需要优化治疗策略.
- 确定最有效的治疗方法对于改善患者的治疗结果至关重要.
研究的目的:
- 系统地审查和对中枢神经系统NGGCTs的治疗方式进行元分析.
- 确定与降低失败率和改善结果相关的干预措施.
主要方法:
- 在主要数据库 (Medline,Embase,Web of Science,Cochrane Library) 进行全面的文献搜索,截至2024年9月.
- 包括所有关于中枢神经系统NGGCT患者的研究,采用信息治疗方法.
- 计算聚合风险比率 (RR) 和95%置信区间 (CI) 用于治疗比较.
主要成果:
- 总体切除 (GTR) 与非GTR相比,失败率降低了28% (RR=0.72).
- 脊辐射 (CSI) 在局部NGGCT中显著降低了失败率 (RR=0.53).
- 化疗放射治疗的失败风险比单独放射治疗低27% (RR=0.73),组合化疗增加了急性毒性,扩大了RT场增加了晚期毒性.
结论:
- 总体切除 (GTR) 和脊辐射 (CSI) 与中枢神经系统NGGCT的更好的结果有关.
- 组合化疗进一步提高了疗效,使得潜在的辐射疗法总剂量减少.
- 这些发现支持采用多式联运方法来优化CNS NGGCT管理.
相关概念视频
Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...


